Validation of the ETNA-MS device for assessing disability in Multiple Sclerosis patients

ETNA-MS Device Validation Study

Observational Innodem Neurosciences · NCT06256731

This study is testing a new eye-tracking device to see if it can accurately measure disability in people with Multiple Sclerosis compared to traditional doctor evaluations.

Quick facts

Study typeObservational
Enrollment60 (estimated)
Ages18 Years and up
SexAll
SponsorInnodem Neurosciences Industry-sponsored
Locations5 sites (Phoenix, Arizona and 4 other locations)
Trial IDNCT06256731 on ClinicalTrials.gov

What this trial studies

This observational study aims to validate the effectiveness of the ETNA-MS device developed by Innodem in assessing the disability status of patients with Multiple Sclerosis (MS). The study will involve a multi-site cross-sectional design where eligible MS patients will undergo eye-tracking assessments to determine their Expanded Disability Status Scale (EDSS) scores. The results from the device will be compared to in-person evaluations conducted by neurologists to assess agreement in disability status. Participants will also undergo brief functional and cognitive assessments to provide a comprehensive understanding of their condition.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of Multiple Sclerosis and an EDSS score between 1.0 and 4.5.

Not a fit: Patients with significant neuropsychiatric disorders or other neurological conditions that impair eye movements may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the accuracy and efficiency of disability assessments in MS patients, leading to better-informed clinical decisions.

How similar studies have performed: While the approach of using eye-tracking technology for disability assessment is innovative, similar studies have shown promise in enhancing diagnostic accuracy in neurological conditions.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Able to provide informed consent
* Aged 18 years or older at the time of enrolment
* Able to read in either English, Spanish or French
* Able to read the oculomotor task on-screen instructions at the testing distance (45 cm) with or without corrective lenses
* Confirmed diagnosis of MS as per the Macdonald criteria, irrespective of MS subtype (relapsing-remitting (RRMS), secondary-progressive (SPMS), primary-progressive (PPMS), and progressive-relapsing (PRMS))
* Neurologist-determined EDSS score between 1.0-4.5

Exclusion Criteria:

* Evidence or medical history of a neuropsychiatric disorder such as schizophrenia and autism, which are known to impair eye movements and oculomotor control.
* Presence of comorbid neurological conditions causing significant eye movement anomalies (such as strabismus, cranial nerve palsy, stroke-causing hemianopsia).
* Diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments.
* Having started a new prescription medication or having changed the dose of a medication known to influence ocular motor visual function (e.g. benzodiazepines, antipsychotics, and anticonvulsants) within the past three months.
* Participants with non-disease related physical impairments to a leg, hand, or arm (e.g., broken bone or severe sprain) that would not allow completion of the assessments.
* Having an EDSS score for which the desired sample size has been reached.

Where this trial is running

Phoenix, Arizona and 4 other locations

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Multiple Sclerosis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.